Atara Biotherapeutics Inc (NASDAQ:ATRA) Director Carol Giltner Gallagher sold 2,500 shares of Atara Biotherapeutics stock in a transaction on Monday, June 18th. The stock was sold at an average price of $44.78, for a total transaction of $111,950.00. Following the sale, the director now directly owns 110,592 shares of the company’s stock, valued at approximately $4,952,309.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Carol Giltner Gallagher also recently made the following trade(s):
- On Wednesday, May 16th, Carol Giltner Gallagher sold 273 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $46.06, for a total transaction of $12,574.38.
Shares of Atara Biotherapeutics traded down $0.70, hitting $44.50, on Tuesday, MarketBeat Ratings reports. The stock had a trading volume of 726,400 shares, compared to its average volume of 829,822. Atara Biotherapeutics Inc has a twelve month low of $12.65 and a twelve month high of $54.45. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -11.13 and a beta of 2.61.
ATRA has been the subject of a number of analyst reports. Jefferies Financial Group lifted their target price on shares of Atara Biotherapeutics from $30.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, March 5th. JPMorgan Chase & Co. initiated coverage on shares of Atara Biotherapeutics in a report on Tuesday, April 10th. They issued an “overweight” rating and a $56.00 price target for the company. BidaskClub lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 1st. Canaccord Genuity reissued a “buy” rating and issued a $70.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, March 13th. Finally, William Blair reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, April 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $43.33.
Hedge funds have recently made changes to their positions in the company. Riverhead Capital Management LLC acquired a new position in shares of Atara Biotherapeutics in the 1st quarter valued at $100,000. SG Americas Securities LLC acquired a new position in Atara Biotherapeutics in the 1st quarter worth $107,000. Principal Financial Group Inc. acquired a new position in Atara Biotherapeutics in the 1st quarter worth $214,000. Teacher Retirement System of Texas acquired a new position in Atara Biotherapeutics in the 1st quarter worth $260,000. Finally, Wasatch Advisors Inc. acquired a new position in Atara Biotherapeutics in the 1st quarter worth $395,000. 98.37% of the stock is owned by institutional investors.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.